Table 1.

The characteristics of the patients

No.	Age	Sex	HHV8	Subsequent / Concurrent	Transformed Subtype	CD treatment	Lymophoma treatment	Follow up
1	58	Male	+	Subsequent	Large B-cell lymphoma (plasmablastic)	/	/	NA [7]
2	68	Female	NA	Subsequent	PTCL-U	Chinese Medicine	Chidamid、GemOx、GDP	Survival [8]
3	58	Male	NA	Concurrent	HD, nodular sclerosis	VBM + Radiotherapy		NA [9]
4	43	Male	+	Concurrent	PEL	Restarted cART, declined proposed chemotherapy of rituximab		NA [10]
5	25	Male	+	Concurrent	PEL	V-Epoch, ICE + R, allo-HCT, daratumumab+Gemcitabine+Oxaliplatin		Death [11]
6	37	Male	NA	Subsequent	PTCL、LDCHL	CHOP	IVAM, BEAM, auto-PBSCT for PTCL, ABVD for HD, DHAP for both	Death [12]
7	73	Male	+	Subsequent	PEL	cyclophosphamide and prednisone	doxorubicin, vincristine and steroiss	Death [13]
8	57	Female	NA	Concurrent	Primary cutaneous MZBL	watch and wait for 2 years and CHOP		Death [14]
9	46	Male	NA	Subsequent	DLBCL	2-CDA	anthracyclin-based chemotherapy, DHAP, MINE	Death [15]
	62	Male	+	Subsequent	PTCL	2-CDA	Chlorambucil, prednisone	Death [15]
10	30	Male	NA	Subsequent	HD, mixed cellularity	radiotherapy	chemotherapy	Survival [16]
	18	Male	NA	Subsequent	HD, nodular sclerosis	Chemotherapy, Radiotherapy	chemotherapy	Survival [16]
	40	Male	NA	Subsequent	HD, nodular sclerosis	radiotherapy	chemotherapy	Survival [16]
11	48	Male	+	Subsequent	PEL	HAART	early death	Death [17]
	67	Male	+	Subsequent	PEL	HAART	early death	Death [17]
	41	Male	+	Subsequent	PEL	HAART	early death	Death [17]
	41	Male	+	Subsequent	PEL	HAART, Splenectomy	CHOP	Death [17]